FDAsafety guidance66% confidence
FDA TA — CENOBAMATE (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Aurobindo Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA219473. Sponsor: AUROBINDO PHARMA LIMITED. Submission status: TA. Submission type: ORIG. Review priority: STANDARD. Active ingredients: CENOBAMATE.
Supporting Context
- Therapeutic area
- Neurology · Antiepileptic
- Sub-indication
- General
Related signal: FDA Accepts Aurobindo's Application for Cenobamate